Home | What Rishi Sunak can do for the UK pharma industry
In this issue
Contents
CSafe
Tripletree
Briefing
Industry news
The pharma industry briefing
BEA Technologies
Mimotopes Company Insight
Mimotopes
Comment
GSK speeds up the race to market first RSV vaccine for older adults
Biden’s directive on foreign biotech investments impacts manufacturers
Novo Nordisk targets FDA approval for once-weekly insulin after Phase III data
‘Twindemic’ risks warrant immediate steps in Europe and the US
A game of two halves for Roche’s recently approved wet AMD assets
Dr. Paul Lohmann
Nipro
In Depth
What Rishi Sunak can do for the UK pharma industry
Inside the European mass shift to data-driven health solutions
Chronic drug shortages signal difficult outlook for cardiovascular care
Can gene therapies for haemophilia defend their high price tags?
Trial termination analysis unveils a silver lining for patient recruitment
New dawn for the EU's joint procurement crisis response
Skyepharma
Bio Image Systems Inc.
In Data
The pharma industry found it easier to fill AI vacancies in Q3 2022
Internet of things hiring levels in the pharma dropped in October 2022
Artificial intelligence hiring levels in the pharma dropped in October 2022
Baxter
Events
Next issue
11/21/2022 00:00:00
Go to article:
Home | What Rishi Sunak can do for the UK pharma industry
Go to article:
In this issue
Go to article:
Contents
Go to article:
CSafe
Go to article:
Tripletree
Go to article:
Briefing
Go to article:
Industry news
Go to article:
The pharma industry briefing
Go to article:
BEA Technologies
Go to article:
Mimotopes Company Insight
Go to article:
Mimotopes
Go to article:
Comment
Go to article:
GSK speeds up the race to market first RSV vaccine for older adults
Go to article:
Biden’s directive on foreign biotech investments impacts manufacturers
Go to article:
Novo Nordisk targets FDA approval for once-weekly insulin after Phase III data
Go to article:
‘Twindemic’ risks warrant immediate steps in Europe and the US
Go to article:
A game of two halves for Roche’s recently approved wet AMD assets
Go to article:
Dr. Paul Lohmann
Go to article:
Nipro
Go to article:
In Depth
Go to article:
What Rishi Sunak can do for the UK pharma industry
Go to article:
Inside the European mass shift to data-driven health solutions
Go to article:
Chronic drug shortages signal difficult outlook for cardiovascular care
Go to article:
Can gene therapies for haemophilia defend their high price tags?
Go to article:
Trial termination analysis unveils a silver lining for patient recruitment
Go to article:
New dawn for the EU's joint procurement crisis response
Go to article:
Skyepharma
Go to article:
Bio Image Systems Inc.
Go to article:
In Data
Go to article:
The pharma industry found it easier to fill AI vacancies in Q3 2022
Go to article:
Internet of things hiring levels in the pharma dropped in October 2022
Go to article:
Artificial intelligence hiring levels in the pharma dropped in October 2022
Go to article:
Baxter
Go to article:
Events
Go to article:
Next issue